Respiratory Reviews

The ODPRN conducted a drug class review on inhaled corticosteroids plus long-acting beta 2-agonists (ICS+LABA) combination products for the management of patients with asthma and chronic obstructive pulmonary disease (COPD), as well as long-acting muscarinic antagonists (LAMAs) for COPD. All three reviews were conducted between November 2013 and April 2015.

Please view the final documents for each review below.

Respiratory Reviews

Reimbursement Option Recommendations
Final Reimbursement Option Recommendations

Citizen’s Panel

Respiratory Reviews Citzen’s Panel Report

Final Publications
Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis

ICS + LABA for COPD: Final Review Documents

Final Reports and Reimbursement Options

Click to view the complete infographic

Click to view the complete research summary

Final Comprehensive Research Plans

ICS + LABA for Asthma: Final Review Documents

Final Reports and Reimbursement Options

Click to view the complete infographic

Click to view the complete research summary

Final Comprehensive Research Plans

Stakeholder Feedback
Comments from stakeholder on the draft report for ICS+LABAs for asthma

LAMAs for COPD: Final Review Documents

Final Reports and Reimbursement Options

Click to view the complete infographic

Click to view the complete research summary

Final Comprehensive Research Plans

Stakeholder Feedback

Any questions? Contact us at info@odprn.ca.

Please note that this report is NOT COMPLETE and is still in progress. Click below if you would like to continue.